between three and five-fold. Therefore, contacts should be the main focus of a future leprosy control strategy.
|
|
- Edwina Hampton
- 5 years ago
- Views:
Transcription
1 1
2 Introduction Hansen's bacillus (Mycobacterium leprae) is considered a microorganism of high infectivity and low pathogenicity and virulence. It is transmitted via nasal oropharyngeal secretions and breaks in the skin of infected patients. Therefore, the main form of transmissibility is inter-human and the greatest risk of contagion is cohabitation with these patients. It is estimated that most individuals have a natural resistance to Mycobacterium leprae (M. leprae) and that some are prone to developing a severe form of the disease, the multibacillary forms. Studies on exogenous reinfection and endogenous reactivation in chronic diseases, such as tuberculosis and leprosy, show that susceptible individuals become infected by the bacillus through contact with multibacillary patients. The number of new leprosy cases has remained constant over the past years (since 2005), indicating that transmission of Mycobacterium leprae, the causative agent of leprosy, is ongoing. The basic intervention is multidrug therapy (MDT) given to newly found leprosy cases, but this seems to be insufficient to decrease the number of new cases. The main risk of exposure to M. leprae is in close contacts of new, untreated cases. Epidemiological studies have shown that the chance of finding a previously undiagnosed leprosy patient is ten times higher in household contacts of leprosy patients than in the general population, and the chance of finding leprosy among different categories of neighbors and social contacts is 2
3 between three and five-fold. Therefore, contacts should be the main focus of a future leprosy control strategy. Post Exposure Chemoprophylaxis is any preventive medical treatment started immediately after exposure to a pathogen, in order to prevent infection by the pathogen and the development of disease. In leprosy, the preventive strategy consists of employing medications to prevent the infection by M. leprae in people with a higher risk of exposure to the disease, i.e. those in contact with the patient. Trials with rifampicin used as chemoprophylaxis for contacts of leprosy patients have shown it to be effective. A meta analysis summarized 7 RCTs with a total of participants to conclude that Chemoprophylaxis is effective in lowering the incidence of leprosy in contacts of patients diagnosed with the disease. Chemoprophylaxis provided 60% protection against leprosy. 3
4 Preparatory activities for Post Exposure Prophylaxis (PEP) Necessary preparatory activities need to be undertaken before starting single dose administration of rifampicin in the target population. Sensitization/ orientation meetings need to be conducted for Medical Officers, PHN, NMS, MPW, PMW and ASHA etc. Necessary IEC activities must be carried out atleast one week before starting the activity to generate awareness and ensure acceptability of same, amongst community. Single dose rifampicin chemoprophylaxis should be administered in the motivated community members willing to accept prophylactic dose. District Leprosy Officers should supervise all the preparatory activities with the support from Medical Officers. Eligibility criteria for PEP Inclusion criteria 1. A person who has been living/working/having social activities for more than three months and 20 hrs/wk with a newly detected case of leprosy in the last 1 yr. 2. Age 2 years. Exclusion criteria 1. Pregnant women (PEP can be given after delivery). 2. People receiving rifampicin therapy for any reason in the last two years (e.g. for tuberculosis [TB] or 4
5 leprosy treatment, or as a contact from another index case). 3. People with a history of liver disorders (ask for H/o jaundice, right sided abdominal pain and swelling, swelling in legs and ankles, pale coloured stool) or renal disorders (ask for H/o decreased urine output, swelling in legs and ankles,h/o high BP). 4. People who have possible signs and/or symptoms of leprosy. 5. People who have possible signs and/or symptoms of TB (patients having any of the following symptoms should be screened for TB: cough for more than two weeks, night sweats, unexplained fever, weight loss). 6. Person with acute febrile illness. Post Exposure Prophylaxis with Rifampicin (Directly Observed Rifampicin Supervised DORS) After confirmation of a case detected during LCDC, the PHC MO will inform MPW of the concerned SC to take necessary action. Paramedical worker/mpw will visit house of the confirmed case along with ASHA. Household and close contacts will be identified and screened for leprosy, any suspected will be referred to MO for confirmation. 5
6 All contacts other than those suspected for leprosy will be screened for any exclusion criteria. The contacts not meeting exclusion criteria will be given single dose of rifampicin chemoprophylaxis. Suspect cases if confirmed will be treated as any other confirmed case and will be given MDT and further contacts will be identified for PEP. In case any contact is not available at home, exclusion criteria will be assessed with the help of family members by MPW and prophylactic dose will be handed over to ASHA for administration. In all cases, the administration of PEP has to be directly observed. Contact screening, in case the index case is a child In case the index case is a child ( 2yrs and <14yrs) everything will be done as in point 1 to 8. In addition to the above home visit to the class mates of the child living in the same locality must be done to screen them for leprosy and checking eligibility for PEP. In case of non availability of all or any contact at home during visit of the worker, the eligibility for PEP of all or same must be checked by MPW/ PMW through enquiry with other family members. Afterward, rifampicin and eligibility formats for the persons not checked for eligibility, must be handed over to ASHA with the responsibility to ensure the consumption of same by the absentee/s contact 6
7 after checking for the eligibility. The filled in format for eligibility must be submitted back to MPW/ PMW. If during screening of contacts a suspected case of leprosy is identified the referral of same may be done to the Medical officer of the nearest health facility for confirmation. If the suspect confirmed as a leprosy patient same may be treated as per the standard guidelines, if not the post exposure prophylaxis i.e., rifampicin to be given. Safety/adverse event management The adverse events following administration of single dose of rifampicin rarely occur. However, likely adverse drug reactions are upset stomach, heartburn, nausea, headache, drowsiness, or dizziness which will be managed as per standard treatment protocols. In addition the persons may be educated by MPW during the visit only about that this medication may produce a harmless, reddish coloration of urine, sweat, saliva or tears. Procedure in the case of an Adverse Event In addition to the above mentioned symptoms, if any adverse drug reaction is noticed by the person/ contact himself/herself after administration of rifampicin. The case must report to Medical Officer of PHC for further management or rerferral to the neareast hospital. Monitoring and supervision The Medical Officer of the PHC is responsible for ensuring screening of all the contacts of each and every leprosy patient. The MO has also to ensure that the guidelines specified for inclusion and exclusion criteria is being 7
8 followed while screening of contacts. The MO PHC will also be responsible for adverse event management. Procurement 1) Procurement of rifampicin would be done by the state. 2) Calculation of the requirement based on yield of cases from LCDC and calculation of cost of the required quantity (assume 20 contacts /case). Reporting The data collection has to be done by PMW/ MPWs and filled forms has to be submitted from field/ Sub Centre to corresponding PHC every day. MO PHC must verify the completeness of the forms through random selection. The data from District to State may be sent on weekly basis. The data will be transmitted to CLD under the following heads: 1) Total no. of index cases 2) Total no. of contacts screened 3) Total no. of contacts diagnosed as leprosy 4) Total no. of contacts found eligible for PEP 5) Total no. of PEP administered as DORS 8
9 Chemoprophylaxis Operational definitions Annexure I Post-exposure prophylaxis with one or more antibiotics given to contacts of an infectious disease case. A single dose of rifampicin is used to reduce the risk of developing leprosy in contacts of leprosy patients (index cases). Contact Contact category Someone who has had prolonged regular or interrupted contact with an index case during the last one year. The time period of contact will be 3 months (cumulative) and 20 hrs / wk. This is based on physical proximity to the index case. The categories are family contacts, household contacts, neighbour contacts and social contacts. Family contacts comprise of all family members.however, if a family member has been away due to reasons eg work or education during the last 1 year, then he will not be included among contacts. Household contacts are people living in the same house as the index case. Neighbour contacts would comprise of are all people living in 3 houses on either side and 3 houses across the street from the index case. Social contacts are all people with whom the index case is in contact for more than 20 hrs per week for a cumulative of 3 months or more. 9
10 Contact screening Leprosy patient Single-dose rifampicin prophylaxis Index case Examination of a contact having been in physical proximity to the index case to determine if they have signs or symptoms of leprosy. A leprosy patient is defined as someone who has one of three cardinal signs and has not completed a course of MDT. A new case of leprosy is defined as someone who has one of three cardinal signs and has not consumed even a single dose of MDT/started a course of MDT. This definition is in the national guidelines and based on the WHO definition. Post-exposure prophylaxis in which a single dose of rifampicin, with dosage based on weight, is given to contacts of an index case. In this document single dose rifampicin prophylaxis is referred as Post-Exposure-Prophylaxis (PEP). > 35 kg 600 mg kg 450 mg < 20 kg mg/kg Any confirmed case diagnosed for the first time as leprosy case 10
11 Annexure II Human resources: roles and responsibilities S.No. Staff Involved 1 MPW/ PMW/ ASHA 2. NMS/ PHN Roles and Responsibilities a. Find index leprosy patient b. Carry out house visit c. Confirm the start of MDT for index case d. Inform about leprosy prevention and chemoprophylaxis e. List 11 neighborhood contacts on contact form f. Collect data on contact form g. Screen for leprosy h. Bring contacts suspected for leprosy to MO i. Record referral in contact form j. Check eligibility for PEP (PMW/MPW) k. Give PEP if eligible(pmw/mpw) l. Record eligibility and SDR in contact form m. Refer to PHC in case of adverse events a. Supervision of field activity of MPW/ PMW/ ASHA 3. MO PHC a. Examine contacts suspected of leprosy or TB b. Responsible for distribution of rifampicin c. Management of adverse reactions 4. DLO/ State Leprosy Officer (NLEP) a. Leprosy expert supervision of field level staff and Mos. b. Give training 11
12 Annexure III SAMPLE FORMATS INDEX CASE INFORMATION: Name: DOB: Gender: Date of Diagnosis: Registration number: Type of leprosy (PB-MB): Disability: Y/N Date of start of MDT: 12
13 CONTACT FORM: Name: Gender: Registration No. of contact: Registration number of index case: Date of contact screening: DOB: Annexure IV Type of contacts: relative/neighbour/social/temporary Inclusion criteria for rifampicin: 1. Person has been living/working/having social activities for more than three months. Y/N 2. Age 2 years. Y/N Exclusion criteria: 1. Pregnancy Y/N 2. Rifampicin therapy for any reason in the last two years (e.g. for tuberculosis [TB] or leprosy treatment, or as a contact from another index case) Y/N 3. History of liver disorders (ask for H/o jaundice, right sided abdominal pain and swelling, swelling in legs and ankles, pale coloured stool) Y/N 4. History of renal disorders (ask for H/o decreased urine output, swelling in legs and ankles, H/o high BP) Y/N 5. Possible signs and/or symptoms of leprosy. Y/N 6. Presence of acute febrile illness. Y/N Whether eligible for chemoprophylaxis: Y/N Date of Rifampicin administered - / / Name: Sign of MPW/PMW: 13
14 14
Guidelines for Post Exposure Chemoprophylaxis with Single dose Rifampicin
Guidelines for Post Exposure Chemoprophylaxis with Single dose Rifampicin Background Hansen's bacillus (Mycobacterium leprae) is considered a microorganism of high infectivity and low pathogenicity and
More informationDrug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment
Drug Resistant Tuberculosis Self-reporting of Drugrelated Adverse Events During Treatment Introduction This information has been prepared for people with tuberculosis (TB) that is resistant to the commonly
More informationLatent tuberculosis infection
EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent
More informationLTBI Videos-Treatment
LTBI Videos-Treatment This program is presented by the Global Tuberculosis Institute and is based on recommendations from the Centers for Disease Control and Prevention. This is the third in a series of
More informationResearch Article The Burden of New Leprosy Cases in India: A Population-Based Survey in Two States
ISRN Tropical Medicine Volume 2013, Article ID 329283, 8 pages http://dx.doi.org/10.1155/2013/329283 Research Article The Burden of New Cases in India: A Population-Based Survey in Two States Anil Kumar
More information20 TH APRIL 2012 AT SILVER SPRING HOTEL NAIROBI
Post Leprosy Elimination and Reemergence of Leprosy in HIV/AIDS Era: Where have we reached, what needs to be done to reach the desired goal; a Kenya without Leprosy 20 TH APRIL 2012 AT SILVER SPRING HOTEL
More informationGUIDELINES FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF LEPROSY EXECUTIVE SUMMARY
GUIDELINES FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF LEPROSY EXECUTIVE SUMMARY Background Leprosy is a disease that predominantly affects the skin and peripheral nerves, resulting in neuropathy and
More informationResearch Article WHO Multidrug Therapy for Leprosy: Epidemiology of Default in Treatment in Agra District, Uttar Pradesh, India
BioMed Research International Volume 215, Article ID 7584, 6 pages http://dx.doi.org/1.1155/215/7584 Research Article WHO Multidrug Therapy for Leprosy: Epidemiology of Default in Treatment in Agra District,
More informationHuman infection with pandemic (H1N1) 2009 virus: updated interim WHO guidance on global surveillance
Human infection with pandemic (H1N1) 2009 virus: updated interim WHO guidance on global surveillance 10 July 2009 Background This document updates the interim WHO guidance on global surveillance of pandemic
More informationCase studies. Self Assessment-I. Case Studies: Programme Management & Treatment with MDT. Case 1:
Self Assessment-I Case studies Case Studies: Programme Management & Treatment with MDT Case 1: Rahman, 35 years old male, on his visit to health center for treatment of his son, was diagnosed to be suffering
More informationPeople who experience gender based violence are more at risk of HIV.
Know the HIV risk People who experience gender based violence are more at risk of HIV. HIV Human Immunodeficiency Virus is the virus that causes AIDS by interfering with the body s ability to fight off
More informationTB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)
TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global
More informationInformation. Leprosy can be easily cured. for the Patient
Information for the Patient About leprosy They will be cured of leprosy if they take the drugs in the blister packs as advised. They must complete a full course of treatment: 6 blisters for PB patients
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationEarly diagnosis of leprosy and the care of persons affected by the disease in a low endemic area Chen, S.
UvA-DARE (Digital Academic Repository) Early diagnosis of leprosy and the care of persons affected by the disease in a low endemic area Chen, S. Link to publication Citation for published version (APA):
More informationAll you need to know about Tuberculosis
All you need to know about Tuberculosis What is tuberculosis? Tuberculosis is an infectious disease that usually affects the lungs. Doctors make a distinction between two kinds of tuberculosis infection:
More informationLEAP Leprosy Elimination and Awareness Program
LEAP Leprosy Elimination and Awareness Program Soe Zeya Tun / Reuters Conquering the Leprosy Last Mile : The Role Of Mobile-Phones Dr. Phillip Olla Audacia Bioscience Leprosy the Facts a chronic disease
More informationMEDICAL QUESTIONNAIRE (male)
MEDICAL QUESTIONNAIRE (male) Slievemore Clinic, Old Dublin Road, Stillorgan, Co. Dublin. Tel 01-2000501/502 Fax: 01 2780248 The appointment comprises of a discussion about this questionnaire and a subsequent
More informationTB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks
1 TB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks 2 Page 1 4 NHS Lothian Infection Prevention and Control Study Day On
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationSilver Child Development Center New Patient Questionnaire. Relation (circle) Biological Mother Stepmother Adoptive Mother
Silver Child Development Center New Patient Questionnaire Today s Date Mother s Name First Last Date of Birth Relation (circle) Biological Mother Stepmother Adoptive Mother Foster Mother Other Father s
More informationPatient Medical History Form
Patient Medical History Form Name: DOB: Sex: M F Street Address: City: State: Zip: Home Phone: Work Phone: Cell Phone:_ Email: Emergency Contact: Phone: Primary Care Physician: Phone: How did you hear
More informationInstructions: Please bring these forms to your Physical Examination & TB Test and have the Doctor fill them out. (Where applicable)
Instructions: Please bring these forms to your Physical Examination & TB Test and have the Doctor fill them out. (Where applicable) 1. The physician s examination certification form. Ask your doctor to
More informationBloodborne Pathogens. By Deborah Massarella RN, MSN
Bloodborne Pathogens By Deborah Massarella RN, MSN 2010, 2014 Objectives At conclusion of in-service learners will: 1. Identify two types of personal protective equipment. 2. Identify two prevention measures
More informationHow does HBV affect the liver?
Hepatitis B Why is the liver important? Your liver is a vital organ that performs many essential functions. It s the largest solid organ in the body and is located under your rib cage on the upper right
More informationPackage leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime
Package leaflet: Information for the user Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPlease have your health insurance card(s), a valid picture ID, and any applicable copayment ready when you check-in.
Please have your health insurance card(s), a valid picture ID, and any applicable copayment ready when you check-in. We have enclosed a questionnaire for you to complete and bring to the visit. Please
More informationWHO Technical Consultation on the severity of disease caused by the new influenza A (H1N1) virus infections
WHO Technical Consultation on the severity of disease caused by the new influenza A (H1N1) virus infections Original short summary posted 6 May 2009. Revised full report posted May 9 2009. On 5 May 2009
More informationAdvisory on Malaria. What is Malaria? 21 November Malaria is a serious, lifethreatening
21 November 2018 Advisory on Malaria What is Malaria? Malaria is a serious, lifethreatening disease causes by Plasmodium parasite which is transmitted to humans from the bite of a female Anopheles mosquito.
More informationnevirapine, stavudine and lamivudine
nevirapine, stavudine and lamivudine Information on starting treatment with: nevirapine (NVP) + stavudine (d4t) + lamivudine (3TC) Nevirapine, stavudine and lamivudine (non-fixed dose) 2 Lead in dosing
More informationTuberculosis (TB) how do we treat it?
Tuberculosis (TB) how do we treat it? Read this. Here is how you will be cured. You will be cured if you take your medicines every day during the whole treatment. You are not alone, let s do this together!
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationStandard Precautions Protecting Yourself From Risk. Compiled by Florida State University Institute for Family Violence Studies
Standard Precautions Protecting Yourself From Risk Compiled by Florida State University Institute for Family Violence Studies Case Scenario 1 And keep others safe around you? Case Scenario 1 Commonly called
More informationDefinitions. Appendix A
Definitions Appendix A 1. Blood means human blood, human blood components, and products made from human blood. 2. Bloodborne Pathogens means pathogenic microorganisms that are present in human blood and
More informationAntivirals for Avian Influenza Outbreaks
Antivirals for Avian Influenza Outbreaks Issues in Influenza Pandemic Preparedness 1. Surveillance for pandemic preparedness eg. H5N1 2. Public health intervention eg. efficacy, feasibility and impact
More informationREMICADE Infliximab Consumer Medicine Information
REMICADE Infliximab Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about It does not contain all the available information. It does not take the place
More informationChapter 2 Hepatitis B Overview
Chapter 2 Hepatitis B Overview 23 24 This page intentionally left blank. HEPATITIS B OVERVIEW Hepatitis B Virus The hepatitis B virus (HBV) belongs to the Hepadnaviridae family and is known to cause both
More informationDiagnosis & Management of Latent TB Infection
Diagnosis & Management of Latent TB Infection Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director Academics, Industry: Research, Diagnosis, Public Health, Academics Adviser: Laboratory Operations,
More informationWHOPAR part 3 Suppliers submission of the SRA approved text. Package Leaflet: Information for the user
Package Leaflet: Information for the user Ethambutol Atb 250 mg Ethambutol hydrochloride Ethambutol Atb 400 mg Ethambutol hydrochloride Read all of this leaflet carefully before you start using this medicine
More informationAre You Ready For A Measles Outbreak? Lessons from Minnesota 2017 Outbreak
Are You Ready For A Measles Outbreak? Lessons from Minnesota 2017 Outbreak Presentation to MCAAP December 6, 2017 Immunization Initiatives Webinar Twitter: @InfectiousPS Disclosure The speakers have been
More informationChanging Trends of Leprosy in Post Elimination Era - A Study from an Endemic Area
Indian J Lepr 2017, 89 : 23-27 Hind Kusht Nivaran Sangh, New Delhi http://www.ijl.org.in Original Article Changing Trends of Leprosy in Post Elimination Era - A Study from an Endemic Area 1 2 3 R Murugaiyan,
More informationICM VI-09 DEFINITION REFERENCES
TITLE/DESCRIPTION: MANAGEMENT OF SELECTED AIRBORNE AND DROPLET INFECTIOUS DISEASE EXPOSURES IN HEALTHCARE WORKERS INDEX NUMBER: EFFECTIVE DATE: APPLIES TO: ISSUING AUTHORITY: 01/01/2009 01/01/2013 All
More informationPatient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol
Patient leaflet: Information for the user Paracetamol Galpharm 500mg tablets paracetamol [For medicines available only on prescription:] Read all of this leaflet carefully before you start taking this
More informationHepatitis B is a virus that attacks the liver. It is highly infectious. Hepatitis B is transmitted primarily
BLOOD BORNE PATHOGENS TRAINING FOR SCHOOL STAFF Blood Borne Pathogen (BBP): A blood borne pathogen is defined as an organism found in human blood or other infected body fluids that may cause disease in
More informationChapter 7 Tuberculosis (TB)
Chapter 7 Tuberculosis (TB) TB infection vs. TB disease Information about TB TB skin testing Active TB disease TB risk factors Role of Peel Public Health in TB prevention and control Environmental and
More informationAnnex A: Impact, Outcome and Coverage Indicators (including Glossary of Terms)
IMPACT INDICATORS (INDICATORS PER GOAL) HIV/AIDS TUBERCULOSIS MALARIA Reduced HIV prevalence among sexually active population Reduced HIV prevalence in specific groups (sex workers, clients of sex workers,
More informationOverview Treatment of latent TB infection Meta-analysis 36 months of IPT Screening for TB Adverse events INH Resistance IPT & ART TST Conclusions
202/03/28 Isoniazid preventive therapy: evidence for safety and efficacy Clinician s course Gavin Churchyard/ Liesl Page-Shipp 6 March 202 Overview Treatment of latent TB infection Meta-analysis 36 months
More informationHepatitis B. What Is Hepatitis? What Are The Two Stages Of Hepatitis? Published on: 5 Oct 2010
Published on: 5 Oct 2010 Hepatitis B What Is Hepatitis? Hepatitis is an inflammation of the liver. Inflammation causes soreness and swelling. Hepatitis can be caused by many things. Hepatitis is most commonly
More informationInnovations in Interrupting Leprosy Transmission. David Addiss, Task Force for Global Health Santiago Nicholls, Pan American Health Organization
Session Date: Saturday, November 4 Innovations in Interrupting Leprosy Transmission Session Time: Session Location: Session Description: Session Chairs: Session Rapporteur: 1:00pm 4:00pm Severn I This
More informationMEDICAL QUESTIONNAIRE (female)
MEDICAL QUESTIONNAIRE (female) Slievemore Clinic, Old Dublin Road, Stillorgan, Co. Dublin. Tel 01-2000501 The appointment comprises of a discussion about this questionnaire and a subsequent medical examination.
More informationPolicy Objective. This policy applies to all staff employed by NHS Greater Glasgow & Clyde and locum staff on fixed term contracts.
1 of 9 Policy Objective To ensure that Healthcare Workers are aware of the actions and precautions necessary to minimise the risk of outbreaks and the importance of diagnosing patients clinical conditions
More informationCHRISTOPHER BROWN D.O. - TRADITIONAL OSTEOPATHY
CHRISTOPHER BROWN D.O. - TRADITIONAL OSTEOPATHY REGISTRATION PAGE Date: Name: Tel: 510-526-5256 (Albany) 415-334-1010 (San Francisco) Fax: 510-526-5547 christopherbrowndo@gmail.com DOB: Age: Sex: Address:
More informationCapital Health Medical Center - Hopewell NEUROSURGICAL-ONCOLOGY Patient History
Capital Health Medical Center - Hopewell NEUROSURGICAL-ONCOLOGY Patient History Please take a few minutes and complete the following questions before you see the doctors so that we may learn a bit more
More informationJUST FOR KIDS SELECTED IMPORTANT SAFETY INFORMATION
JUST FOR KIDS For children ages 6-17 with moderately to severely active Crohn s disease or ulcerative colitis (UC) who haven t responded well to other therapies SELECTED IMPORTANT SAFETY INFORMATION REMICADE
More informationAsyntomatic bacteriuria, Urinary Tract Infection
Asyntomatic bacteriuria, Urinary Tract Infection C. Infectious Diseases Society of America Guidelines for the Diagnosis and Treatment of Asyntomatic Bacteriuria in Adults (2005) Pyuria accompanying asymptomatic
More informationTips to Help Treat Diarrhea, Nausea, and Vomiting Side Effects
Tips to Help Treat Diarrhea, Nausea, and Vomiting Side Effects If you have been prescribed OFEV (nintedanib) capsules for the treatment of idiopathic pulmonary fibrosis (IPF) this brochure can help you
More informationDo you have Iron Deficient Anemia?
Do you have Iron Deficient Anemia? Do you ever just have this overwhelming feeling all day, every day, that you have no energy?! Ever just sat there thinking, I eat well and healthily, I exercise, I take
More informationPlease list any medications you currently taking along with dosage and directions (including birth control, vitamins and OTC medications):
Name: DOB: Date of Appointment: Please list all doctors you currently see (Primary Care Physician and Specialists i.e. Cardiologist): Please list any medications you currently taking along with dosage
More informationManaging the Revised National Tuberculosis Control Programme in Your Area. A Training Course. Modules 1 4
Managing the Revised National Tuberculosis Control Programme in Your Area A Training Course Modules 1 4 1 Course Introduction 2 Ensuring Identification of Tuberculosis Suspects 3 Supporting Laboratory
More informationEXPOSURE (HIV/HEPATITIS) BLOOD & BODY FLUIDS
Page(s): 1 of 11 PURPOSE To set a standardized procedure to ensure that employees are evaluated in a consistent and timely manner.. POLICY A. The treatment of Team Member exposure to bloodborne pathogens
More informationNEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE Thomas R. Frieden, MD, MPH Commissioner
NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE Thomas R. Frieden, MD, MPH Commissioner Interim Guidance on Dosage, Precautions, and Adverse Effects of Antiviral Medications used to Treat or Prevent
More information(sunitinib malate) for Kidney Cancer
Sutent (sunitinib malate) for Kidney Cancer Sutent is a medication used to treat adult patients with kidney cancer that has been surgically removed and at high risk of recurrence, or advanced kidney cancer
More informationPATIENT INFORMATION LEAFLET FOR FEDALOC 30 mg / 60 mg SR TABLETS. Please read this leaflet carefully before you start taking FEDALOC tablets.
1 Module 1.5.5.2 Patient information leaflet PATIENT INFORMATION LEAFLET FOR FEDALOC 30 mg / 60 mg SR TABLETS Please read this leaflet carefully before you start taking FEDALOC tablets. Keep this leaflet.
More informationMedical Bacteriology- Lecture 10. Mycobacterium. Actinomycetes. Nocardia
Medical Bacteriology- Lecture 10 Mycobacterium Actinomycetes Nocardia 1 Mycobacterium Characteristics - Large, very weakly gram positive rods - Obligate aerobes, related to Actinomycetes - Catalase positive
More informationPackage leaflet: Information for the user. Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium)
PACKAGE LEAFLET Package leaflet: Information for the user Pravastatin Actavis 20 mg and 40 mg tablets (pravastatin sodium) Read all of this leaflet carefully before you start taking this medicine because
More informationBlood Borne Pathogens. November 2010
Blood Borne Pathogens November 2010 Objectives Meet requirements of OSHA Standard 29 CFR 1910.1030 OSHA Blood Borne Pathogens Post Test Routes of Transmission Types of Pathogens BSI / PPE Common Diseases
More informationCharacteristics of Mycobacterium
Mycobacterium Characteristics of Mycobacterium Very thin, rod shape. Culture: Aerobic, need high levels of oxygen to grow. Very slow in grow compared to other bacteria (colonies may be visible in up to
More informationLearn how MORPHABOND ER can help manage your pain
Your healthcare provider has prescribed Learn how can help manage your pain What is? MORPHABOND ER (morphine sulfate) extended-release tablets, CII is a strong prescription pain medicine that contains
More informationClinical Practice Guideline
ITBS LTBI ITBS Management 1 of 6 ITBS Contact ITBS Oversight ITBS Disease Professional Advisory 1.0 PURPOSE: 1.1 Provide clinical practice and operational guidance to Public Health Nurses to ensure consistency
More informationleprosy I. Keramidas M.D.
leprosy I. Keramidas M.D. Presentation outline Introduction Classification Diagnosis Some general data Treatment Epidemiological data Introduction Leprosy is a chronic infectious disease caused by Mycobacterium
More informationSOC SEC #: - - Date of Birth: - - Age: yrs. State: Zip Code: Employer:
PATIENT INFORMATION (PLEASE PRINT) SOC SEC #: - - MRN#: Home Phone: Work Phone: Ext: Address: City: Cell Phone: Date of Birth: - - Age: yrs State: Zip Code: Employer: SEX: Male Female Work Address: City:
More informationMEDICAL ASSESSMENT FOR DEFILEMENT
Appendix 1: MEDICAL ASSESSMENT FOR DEFILEMENT Hosp No: Name... Age... Date of Birth... Address. Name of doctor examining patient Date and time of assessment Others present. Consent given by HISTORY Date
More informationTuberculosis (TB) Fundamentals for School Nurses
Tuberculosis (TB) Fundamentals for School Nurses June 9, 2015 Kristin Gall, RN, MSN/Pat Infield, RN-TB Program Manager Marsha Carlson, RN, BSN Two Rivers Public Health Department Nebraska Department of
More informationPrimary Chief Complaint 1. Location 2. When did this begin? 3. How did this begin?
Name Date These questions that you are about to answer are very important for the Doctor. They will enable the doctor make a complete and diagnosis, and provide medical documentation (if needed)to your
More informationReplaces: 02/11/16. Formulated: 7/95 EMPLOYEE TB TESTING
Effective : 02/09/17 Page 1 of 4 PURPOSE: To describe the process where by employees may obtain routine TB skin testing by facility medical staff. POLICY: Employees of the Texas Department of Criminal
More informationClinical Guidance for 2009 H1N1 Influenza and Seasonal Influenza. Barbara Wallace, MD New York State Department of Health (Updated 10/8/09)
Clinical Guidance for 2009 H1N1 Influenza and Seasonal Influenza Barbara Wallace, MD New York State Department of Health (Updated 10/8/09) 1 Outline Clinical assessment Diagnostic testing Antiviral medications
More informationSpots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox
Spots and Pox: Contact Tracing and Follow Up for Measles and Chickenpox Noelle Bessette, MPH Surveillance Specialist New Jersey Department of Health Vaccine Preventable Disease Program Chickenpox Caused
More informationResponse to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria.
Response to Treatment in Sputum Smear Positive Pulmonary Tuberculosis Patients In relation to Human Immunodeficiency Virus in Kano, Nigeria. Yusuf Mohammed, Mukhtar Dauda, Ifeanyi Oyeyi TB/HIV Unit, International
More informationTuberculosis Procedure ICPr016. Table of Contents
Tuberculosis Procedure ICPr016 Table of Contents Tuberculosis Procedure ICPr016... 1 What is Tuberculosis?... 2 Any required definitions/explanations... 2 NHFT... 2 Tuberculosis (TB)... 3 Latent TB...
More informationJoseph S. Weiner, MD, PC Patient History Form
Date: / / NAME: Last First M. I. Age: Sex: q F q M Birthdate: / / What specific questions or goals do you have for this appointment? Please list the names of other clinicians you have seen for this problem:
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION BAVENCIO (buh-ven-see-oh) Avelumab for Injection Solution for Intravenous Infusion Read this carefully before you start
More informationPolicy Group: Safe and Supportive Environment Policies Policy Name: Illness
Policy Group: Safe and Supportive Environment Policies Policy Name: Illness Exclusion of Sick Children and Staff Children and staff will be excluded from School if they are ill with any contagious illness.
More informationHASPI Medical Biology Lab 03
Patient 1001 is a 42-year-old female that is experiencing severe heartburn, abdominal pain, bloating, nausea, and vomiting. Ulcers Bleeding sores in the stomach or intestine Gallbladder Disease Gallstones
More informationSafety Tips from the WorkSafe People
Blood Borne Pathogens Training HIV/AIDS Hepatitis B Determining Exposure Protecting Yourself Preventing Exposure during an Emergency HIV/AIDS Definition: AIDS stands for Acquired Immune Deficiency Syndrome.
More information1. and it is more than 12 hours until your next dose, take the missed dose and continue with your normal schedule
Everolimus Everolimus (Afinitor ) for pancreatic neuroendocrine tumours This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy
More informationDR-TB Patient Treatment Log Book
REPUBLIC OF KENYA MINISTRY OF HEALTH DR-TB Patient Treatment Log Book Patient Name: Patient Reg. No.: VERSION 2016 DR-TB treatment outcome summary Outcome Mark one Date Cured Died Failed Defaulted Transferred
More informationHot Topic: H1N1 Flu (Swine Flu)
Hot Topic: H1N1 Flu (Swine Flu) For additional information go to: http://www.cdc.gov/ swineflu/general_info.htm Note: The information in this document is based on information from the CDC. The CDC site
More informationHaemophilus influenzae, Invasive Disease rev Jan 2018
Haemophilus influenzae, Invasive Disease rev Jan 2018 BASIC EPIDEMIOLOGY Infectious Agent Haemophilus influenzae (H. influenzae) is a small, Gram-negative bacillus, a bacterium capable of causing a range
More informationBLOODBORNE PATHOGENS Online Training for Buncombe County Public School Employees
BLOODBORNE PATHOGENS Online Training for Buncombe County Public School Employees Buncombe County Public Schools require employees to receive annual training for Bloodborne Pathogens. This online training
More informationWhat is the most important information I should know about tenofovir? What should I discuss with my healthcare provider before taking tenofovir?
1 of 6 6/10/2016 4:33 PM Generic Name: tenofovir (ten OF oh vir) Brand Name: Viread What is tenofovir? Tenofovir is an antiviral medicine that prevents human immunodeficiency virus (HIV) or hepatitis B
More informationSECTION OF NEUROSURGERY PATIENT INFORMATION SHEET
SECTION OF NEUROSURGERY PATIENT INFORMATION SHEET EC#: (for office use only) Patient s Name: Today s Date: Age: Date of Birth: Height: Weight: Physician you are seeing today: Marital Status: Married Work
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More informationBasic Epidemiological Indicators for Monitoring Leprosy
Basic Epidemiological Indicators for Monitoring Leprosy There are several epidemiological and operational indicators for monitoring leprosy control activities. The most important are prevalence, incidence,
More informationInflectra for Crohn s disease
Inflectra for Crohn s disease Some important information to get you started with your treatment This booklet is intended only for use by patients who have been prescribed Inflectra. Introduction When you
More informationSwine Influenza Update #3. Triage, Assessment, and Care of Patients Presenting with Respiratory Symptoms
Updated 12:00 p.m. April 30, 2009 Swine Influenza Update #3 Introduction: This document revises our last update which was sent April 28 th, 2009. The most important revisions include the following: 1.
More informationPatient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension
Patient Information VERSACLOZ (VER sa kloz) (clozapine) Oral Suspension Read this Patient Information before you start taking VERSACLOZ and each time you get a refill. There may be new information. This
More informationAdapted and translated by Elizabeth Barrera-Cancedda from the Tuberculosis Resistente rotafolio produced by PARTNERS TB CONTROL Grupo IECA, Peru.
Generic Version: September 2012 Adapted and translated by Elizabeth Barrera-Cancedda from the Tuberculosis Resistente rotafolio produced by PARTNERS TB CONTROL Grupo IECA, Peru. Special thanks go to Socios
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationEpidemiology Update Hepatitis A
December 2011 Epidemiology Update Hepatitis A Hepatitis A Key Points Between 2000 and 2010, 209 cases of hepatitis A were reported in Hennepin County residents. This represents 30% of the cases reported
More information